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Abstract
Objective: Congenital hypogonadotropic hypogonadism (CHH) and constitutional delay of growth and puberty (CDGP) 
represent rare and common forms of GnRH deficiency, respectively. Both CDGP and CHH present with delayed puberty, 
and the distinction between these two entities during early adolescence is challenging. More than 30 genes have been 
implicated in CHH, while the genetic basis of CDGP is poorly understood.
Design: We characterized and compared the genetic architectures of CHH and CDGP, to test the hypothesis of a shared 
genetic basis between these disorders.
Methods: Exome sequencing data were used to identify rare variants in known genes in CHH (n = 116), CDGP (n = 72) and 
control cohorts (n = 36 874 ExAC and n = 405 CoLaus).
Results: Mutations in at least one CHH gene were found in 51% of CHH probands, which is significantly  
higher than in CDGP (7%, P = 7.6 × 10−11) or controls (18%, P = 5.5 × 10−12). Similarly, oligogenicity  
(defined as mutations in more than one gene) was common in CHH patients (15%) relative to  
CDGP (1.4%, P = 0.002) and controls (2%, P = 6.4 × 10−7).
Conclusions: Our data suggest that CDGP and CHH have distinct genetic profiles, and this  
finding may facilitate the differential diagnosis in patients presenting with delayed puberty.
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Introduction
Congenital hypogonadotropic hypogonadism (CHH 
(MIM: 146110)) is a rare disorder affecting approximately 
1 in 4000 births (1). It is caused by GnRH deficiency, 
and subsequently results in altered activation of the 
hypothalamic–pituitary–gonadal (HPG) axis that 
controls sexual maturation and fertility. Clinically, CHH 
presents as absent/incomplete puberty and infertility. It 
is characterized by isolated low sex steroids in the setting 
of low (or inappropriately normal) serum gonadotropins 
in the absence of other hypothalamo-pituitary defects. 
Clinically, CHH is a heterogeneous disorder. In the presence 
of anosmia (the inability to smell) in approximately 50% 
of CHH probands, the condition is termed Kallmann 
syndrome (KS (MIM: 308700)). Other associated 
phenotypes such as hearing loss, synkinesia, renal agenesis, 
ataxia and cleft lip/palate are also observed with variable 
frequency (2). Interestingly, a higher than expected 
proportion (10%) of family members of CHH probands 
report a history of delayed puberty (3). Moreover, reversal 
of hypogonadotropic hypogonadism in CHH patients after 
discontinuing hormone therapy also points to a clinical 
overlap between the two entities (4). Therefore, congenital 
delay of growth and puberty (CDGP), also termed self-
limited delayed puberty, and CHH appear to be part of the 
same clinical spectrum – one being classically described as 
transient (CDGP) and the other as permanent (CHH) (3). 
In contrast to CHH, CDGP is a common disease, observed 
in 2–2.5% of the population (5).
Since the initial genetic report implicating KAL1 
(now ANOS1) (6, 7), the genetics of CHH has been widely 
studied. Similar to its diverse clinical presentation, the 
genetic architecture of CHH is also heterogeneous, with 
several modes of inheritance having been described 
including autosomal dominant, autosomal recessive, 
X-linked and de novo. Mutations in more than 30 genes 
have been shown to cause CHH (2); however, they only 
account for approximately 35% of cases (8). Defects 
in genes involved in GnRH neuron development and 
olfactory system usually result in KS, whereas mutations 
in genes involved in GnRH secretion or homeostasis 
result in normosmic CHH (nCHH). Interestingly, clinical 
overlap between KS and nCHH has been reported, with 
a disease spectrum rather than a binary classification for 
normosmic and anosmic (9). In parallel, genetic overlap 
between KS and nCHH also exists, with several genes 
mutated in both subgroups (2).
Although long thought to be a monogenic disorder, 
frequent observations of incomplete penetrance and 
variable expressivity within and across families suggested 
this model was insufficient to fully explain the observed 
phenotypes in CHH. Indeed, previous work by our team 
and others has shown that oligogenic inheritance (i.e. 
more than one gene mutated in the same individual) 
can at least partially explain some of these phenomena 
(8, 10). Synergistic effects between CHH genes have been 
also described in vitro (e.g. FGF8/FGFR1) (11) and in vivo 
(e.g. KISS1/KISS1R) (12). Oligogenicity has been proposed 
in heterogeneous genetic disorders such as Bardet–Biedl 
syndrome (BBS) (13) and retinitis pigmentosa (14). In 
addition, oligogenicity is also proposed for other endocrine 
diseases such as premature ovarian failure (15, 16) with 
the constellation of more than one gene mutated.
Pubertal timing is a highly heritable trait as up to 
50–80% of the variance is explained by genetic factors 
(17). Consistently, CDGP runs in families with complex 
inheritance pattern (18), but in contrast to CHH, little 
is known about the genetics of CDGP. A recent study 
identified mutations with low frequencies (MAF <2.5%) 
in IGSF10 in 13% of CDGP probands. IGSF10 is a large 
protein that is part of the immunoglobulin superfamily 
and appears to have a developmental role in GnRH neuron 
migration (19). In addition, genome-wide association 
studies (GWAS) evaluating common and rare variants in 
the timing of puberty identified significant associations 
with hundreds of loci, including regions near or within 
ANOS1, TACR3, LEPR and PCSK1 – four known CHH 
genes. Taken together, these loci account for <3% of the 
variance in age of puberty onset (20, 21). In view of the 
possible overlap between the pathophysiology of delayed 
puberty and conditions of GnRH deficiency, few studies 
have searched for mutations in CHH genes in CDGP 
cohorts. A homozygous partial loss-of-function mutation 
in GNRHR was found in two brothers, one with CDGP and 
one with CHH (22). Of 50 CDGP patients investigated for 
mutations in TAC3 and TACR3, only one mutation in a 
single patient was found in the latter gene (23). However, 
a recent study screening 21 CHH genes in a CDGP cohort 
(n = 56) found potentially pathogenic mutations in 14% 
of patients (3). Recently, low frequency (MAF <2.5%) 
potentially pathogenic variants in IGSF10 were found in 
10% of CHH patients (19), suggesting the hypothesis of a 
partial genetic overlap between CHH and CDGP.
Currently, the differential diagnosis between CHH 
and CDGP at early adolescence remains challenging, as 
both conditions present with isolated delay in puberty. 
Further, there are no specific biochemical markers to 
accurately differentiate these two disorders (24). In the 
current study, we explored the genetic architecture of 
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both CHH and CDGP and to investigate whether genetic 
testing could assist in the differential diagnosis. We also 
characterized the genetic overlap between KS and nCHH 
using a comprehensive screening of all CHH genes and 
defined the mutational spectrum of CHH genes in the 
control population.
Subjects and methods
Patient and control cohorts
The study cohort includes 116 CHH probands of European 
descent (n = 61 KS, n = 55 nCHH) with a 2:1 male-to-
female ratio consistent with previous reports of male 
predominance (1). The diagnosis of CHH was determined 
by (1) absent or partial puberty by 17 years (25), (2) low/
normal serum gonadotropin levels in the setting of low 
serum testosterone/estradiol levels, (3) otherwise normal 
anterior pituitary function and (4) normal imaging of the 
hypothalamic–pituitary area (25). Olfaction was assessed 
by self-report and/or formal testing (9) using the UPSIT or 
Sniffin’ Stick tests. When possible, family members were 
recruited for clinical and genetic studies.
The delayed puberty cohort consists of 72 unrelated 
probands with CDGP of primarily Finnish European 
origin and has been previously described in detail (26). 
All patients met the diagnostic criteria for CDGP, defined 
as (1) onset of Tanner genital stage II two SDs later than 
population average (i.e. in boys testicular volume >3 mL 
after 13.5  years of age and in girls Tanner breast stage 
II after 13.0  years of age) (27). Medical history, clinical 
examination and routine laboratory tests were performed 
to exclude chronic illnesses, and the diagnosis of CHH 
was ruled out by spontaneous pubertal development 
at follow-up. All patients were followed until near-full 
pubertal development was attained (i.e., Tanner stage 4).
Ethnically matched controls (non-Finnish European 
(NFE) and Finnish European (FIN)) from the Exome 
Aggregation Consortium (ExAC) (28) were used for 
individual variant and gene mutation frequencies. 
Oligogenicity was assessed using the ‘Cohorte 
Lausannoise’ (CoLaus) control population, consisting of 
405 participants of mixed European origin, phenotyped as 
described by Firmann and coworkers (29). This population-
based cohort was assembled as part of a cardiovascular 
risk study, and therefore, has a typical distribution of 
pubertal age relative to the general population. The ages 
of the cohort participants are 35–75  years old (mean 
51 ± 11 years).
DNA extraction and sequencing
DNA was extracted from peripheral blood leukocytes 
using the PureGene kit (QIAGEN). Exome sequencing 
was performed on CHH and CDGP cohorts using the 
SureSelect V2 or V5 probes (Agilent) or the Nimblegen 
SeqCap EZ Exome V2 (Roche) and sequenced on the HiSeq 
2000 platform (Illumina, San Diego, CA, USA) at either 
BGI (BGI, Shenzen, PRC) or Otogenetics (Otogenetics 
Corp., Atlanta, GA, USA). Exome sequencing on CoLaus 
DNA was performed at the Wellcome Trust Sanger 
Institute (WTSI) as part of a partnership between the 
Institute, the CoLaus principal investigators and the 
Quantitative Sciences department of GlaxoSmithKline 
(GSK, Brentford, UK).
Definition of genes to be screened
‘CHH genes’ are those which met the following criteria: 
(1) identified as CHH genes in Boehm and coworkers 
(2), (2) had publications demonstrating loss-of-function 
variants, (3) had been demonstrated to be expressed in 
organs/tissues relevant for GnRH biology and (4) covered 
by the exome capture probes. Twenty-four genes met these 
criteria: ANOS1, SEMA3A, FGF8, FGF17, SOX10, IL17RD, 
AXL, FGFR1, CHD7, HS6ST1, PCSK1, LEP, LEPR, FEZF1, 
NSMF, PROKR2, WDR11, PROK2, GNRH1, GNRHR, KISS1, 
KISS1R, TAC3 and TACR3. In addition, we screened the 
IGSF10 gene, recently implicated in CDGP and CHH (19).
Bioinformatics analysis and downstream 
variants filtering
Exome sequences from CHH probands, CDGP probands 
and CoLaus controls were analyzed following the 
Genome Analysis Toolkit (GATK) Best Practices (30). The 
computations were performed at the Vital-IT Center for 
High-Performance Computing of the Swiss Institute of 
Bioinformatics. Variants called with a genotype quality 
(GQ) <50 were excluded. The complete set of CHH 
gene variants from the ExAC database was downloaded 
from the ftp site (ftp://ftp.broadinstitute.org/pub/ExAC_
release/release0.3). Annotation was performed using 
SnpEff (31), version 4.0. Intronic variants within ±6 bp 
of exonic boundaries and predicted to affect splicing by 
MaxEnt (32) with a wild-type vs mutated site change of 
±20% were retained, as well as inframe/frameshift indels, 
stop gain, and missense variants. Protein-truncating 
variants (PTVs) were defined as frameshift, stop gain and 
splice variants (28).
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For the purpose of this study, we define as mutations 
(1) rare (MAF <1%) PTVs, (2) rare missense variants 
predicted to be damaging to protein function by at least 
one in silico algorithm (SIFT (33) or PolyPhen-2 (34)) and 
(3) loss-of-function variants based on in vitro studies, 
regardless of in silico predictions.
Statistical analyses
Statistics for individual and oligogenic variants in cases 
vs controls were performed using a two-tailed Fisher’s 
exact test. Gene-based allele frequencies in ExAC were 
calculated dividing the sum of alternate allele counts in 
ethnically matched samples with the average of alleles 
inspected. Gene-collapsed rare variant association 
(RVA) tests in cases vs controls were calculated using 
mutated allele frequencies in a two-tailed Fisher’s exact 
test. Statistical significance in gene-based RVA tests was 
defined using Bonferroni correction, dividing nominal 
significance (0.05) with the number of tests performed 
(i.e. genes analyzed, n = 25); hence, the cutoff to determine 
significance was set at P = 0.002.
Ethics approval and consent to participate
This study was approved by the ethics committee of the 
University of Lausanne. All participants provided written 
informed consent prior to study participation. The 
study protocol was approved by the Ethics Committee 
for Paediatrics, Adolescent Medicine and Psychiatry, 
Hospital District of Helsinki and Uusimaa (and extended 
to encompass Kuopio, Tampere and Turku University 
Hospitals) (570/E7/2003). UK ethical approval was 
granted by the London-Chelsea NRES committee (13/
LO/0257). The study was conducted in accordance with 
the guidelines of The Declaration of Helsinki.
Results
CHH genes are mutated in 51% of CHH probands 
but only in 7% in CDGP probands
Exome sequencing was performed on 116 CHH probands, 
and 59 (51%) harbored mutations in 20 of the 25 genes 
evaluated (Fig. 1A and Supplementary Table 1, see section 
on supplementary data given at the end of this article). 
No mutations were identified in NSMF, FEZF1, PCSK1, LEP 
and LEPR. Nearly two-thirds of familial CHH probands 
carried mutations in CHH genes (27/44, 61%), while the 
frequency in sporadic probands was lower (32/72, 44%) 
(Supplementary Fig. 2).
FGFR1 and CHD7 were the most frequently mutated 
genes in CHH probands (Fig.  1A), and both were 
statistically enriched for mutations compared to ExAC 
NFE controls (Table 1 and Supplementary Fig. 1). All of 
the identified FGFR1 and CHD7 mutations were present in 
a heterozygous state (Supplementary Table 2). In addition, 
a significant enrichment of mutations was observed for 
SOX10, with a prevalence of 4% in CHH patients (Table 1 
and Supplementary Table 1).
Figure 1
KS and nCHH display both shared and 
specific genetic patterns, and CDGP is not 
characterized by genetic overlap with 
CHH. Histograms showing CHH genes and 
IGSF10 mutational prevalence in (A) CHH, 
(B) KS, (C) nCHH, (D) CDGP, (E) CoLaus, 
and (F) ExAC Finnish (FIN) cohorts. The 
prevalence of probands with variants in 
each gene are noted in black for 
nonsynonymous (i.e. missense and 
inframe InDels), white for splicing, and 
gray for nonsense (i.e. frameshift and stop 
gained) variants.
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Exome sequencing identified 7% (n = 5) of CDGP 
probands harboring mutations in the known CHH genes, 
all of which are heterozygous (Fig. 1D and Supplementary 
Table 3). Thus, the genetic profile of the CDGP cohort more 
closely resembles the controls (both ExAC Finnish and 
non-Finnish controls) rather than CHH probands. Among 
the six identified mutations, there were five missense and 
one intronic change predicted to affect splicing. Three 
mutations were private compared to 3307 Finnish ExAC 
controls. Only one CDGP proband harbored two mutated 
genes (oligogenicity) (1.4%, P = 0.002 vs CHH), a similar 
rate as observed in controls ( and Supplementary Table 2). 
Clinically, this CDGP patient had spontaneous puberty at 
14.3 years and achieved normal adult testicular volume 
and testosterone levels over the subsequent 2.4  years, 
thereby excluding a diagnosis of CHH.
Prevalence of putative IGSF10 mutations in  
CHH is similar to CDGP
We found a large number of CHH patients (19/116, 16.4%) 
harboring putative IGSF10 mutations compared to CDGP 
(8/72, 11.1%) (Fig.  1A, B, C and D). Our data did not 
show enrichment for mutations in our cohorts as similar 
frequencies were seen in controls (Fig. 1A, B, C and D).
KS and nCHH show both exclusive and shared 
genetic architectures
We examined the mutational spectrum relative to the 
two subgroups of CHH – KS (n = 61) and nCHH (n = 55). 
Among KS, FGFR1 and CHD7 were the most frequently 
mutated genes, and together with SOX10 are significantly 
enriched when compared to controls (Fig. 1B and Table 1). 
This finding is even more robust when evaluating the KS 
subgroup alone. Similarly, FGF8 showed a prevalence of 
1.6% in KS; yet, this association was not evident in the 
CHH cohort as a whole. Mutations in ANOS1, SEMA3A, 
FGF17 and FGF8 were only found in KS.
Among normosmic probands (nCHH), FGFR1 and 
CHD7 were also the most frequently mutated genes. 
Mutations in GNRHR and TACR3 were only found in 
nCHH (7% and 5%, respectively) (Fig. 1C). Further, FGFR1, 
KISS1, GNRHR and TACR3 were significantly enriched in 
nCHH cases compared to ExAC NFE controls (Table 1).
In addition to FGFR1 and CHD7, six other CHH genes 
(SOX10, IL17RD, AXL, HS6ST1, PROKR2 and WDR11) 
were mutated in both KS and nCHH (Fig. 1B and C). This 
represents an increased genetic overlap in comparison 
to prior report (2). Overall, these results indicate both 
exclusive and shared genetic architectures for both KS and 
nCHH.
nCHH probands are enriched with  
biallelic mutations
Biallelic mutations (i.e. homozygous or compound 
heterozygous changes in the same gene) were found 
exclusively in nCHH (6/55, 11%) and were not seen in 
KS (P = 0.01), CDGP (P = 0.006) or in CoLaus (P = 2.3 × 10−6) 
(Fig. 2). Furthermore, 4/15 (27%) genes mutated in nCHH 
(GNRHR, GNRH1, PROKR2, PROK2, TACR3) only exhibited 
biallelic mutations, consistent with their recessive mode 
of inheritance (Fig. 2C and Supplementary Table 1).
Figure 2
The majority of CHH genes are inherited 
in a oligogenic fashion in CHH probands, 
a trend not observed in CDGP probands 
and CoLaus controls. Histograms showing 
CHH genes mutational prevalence in (A) 
CHH, (B) KS, (C) nCHH, (D) CDGP and (E) 
CoLaus screened individuals. Each bar 
contains the frequency of each gene 
inheritance: monoallelic (gray), biallelic 
(yellow) or oligogenic (red).
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Oligogenicity is a common factor in CHH patients
Oligogenicity was present in 17/116 (15%) of CHH 
probands (Fig.  3) – a higher frequency than previous 
reports of 2.5–7% (8, 10). A significantly lower rate of 
oligogenicity was observed in controls (CoLaus: 2%, 
P = 6.4 × 10−7).
Additionally, although monogenic inheritance was 
more frequent in KS (46%) compared to nCHH (25%, 
P = 0.03), CDGP (6%, P = 3.7 × 10−8) and CoLaus (16%, 
P = 4.6 × 10−7), similar frequencies of oligogenicity were 
identified in both KS (13%) and nCHH (16%) (Fig. 3 and 
Supplementary Table 3).
Among the 20 mutated genes identified in CHH 
patients, 84% (n = 16 genes) participated in oligogenicity 
(Fig. 2A). Of these 16 genes, mutations in IL17RD, HS6ST1, 
KISS1R and TAC3 occurred exclusively in an oligogenic 
manner. ANOS1, FGF17, KISS1 and PROK2 were the 
only genes exclusively showing monogenic inheritance 
(Fig. 2A).
Among possible gene combinations, FGFR1 and CHD7 
was the most frequent pair interaction (n = 4), followed by 
FGFR1/IL17RD and CHD7/HS6ST1 (n = 2) (Fig.  4A). One 
KS proband (Fig.  4B, Pedigree 1) carrying mutations in 
both CHD7 and FGFR1, had two daughters after receiving 
fertility treatment. One of them carried both mutations 
and was eventually diagnosed with KS, while the second 
unaffected daughter did not harbor either of the two 
changes. In Pedigree 2, we identified three mutated 
genes (FGFR1, CHD7 and SOX10) in a KS proband. His KS 
brother showed overlapping FGFR1 and SOX10 mutations. 
As there were no phenotypic differences between the 
proband and his sibling, the CHD7 mutation is likely not 
critical in the etiology of KS for this pedigree. Last, we 
identified a KS proband (Fig. 4B, Pedigree 3) harboring an 
IL17RD mutation inherited from his anosmic mother and 
a de novo FGFR1 mutation. We did not identify any CHH 
gene mutations in the anosmic father or the unaffected 
brother.
The majority of mutations in CHH probands 
are private
When assessing the mutations identified in CHH 
probands, more than half of them (38/68, 56%) were 
not found in the ExAC NFE controls (n = 33  370), and 
therefore, are private.
In total, we identified 1492 putative mutations in 
ExAC NFE controls and 80 mutations in 72/405 (18%) 
CoLaus controls. However, the majority of mutations 
in CoLaus (89%, P = 6.6 × 10−4) (Fig.  2E) occurred in a 
monoallelic pattern. Given the variant-based (rather than 
sample-based) nature of the ExAC database, the allelic 
patterns in these controls could not be assessed.
Protein-truncating variants are enriched in 
CHH probands
PTVs are defined as changes predicted to severely disrupt 
genes, i.e. splicing, frameshift and stop gain variants. 
A large fraction of the discovered mutations in CHH 
probands were PTVs (20/68, 29%), while the frequency 
was significantly lower (5%) in ExAC NFE controls 
(P = 1.0 × 10−9). Overall, 18% (n = 21) of patients in our 
cohort harbored at least one PTV in the known CHH 
genes. Specifically, the CHH cohort was enriched for splice 
variants in FGFR1 (2.6%, P = 1.7 × 10−4) and for frameshift/
stop gain variants in FGFR1 (8%, P = 6.9 × 10−13), SOX10 
(1.7%, P = 1.2 × 10−5) and TACR3 (1.7%, P = 4.9 × 10−3) 
when compared to ExAC NFE.
We observed that 80% of PTVs in CHH were in 
genes with a high constraint to this type of variants (i.e. 
probability of being loss-of-function intolerant – pLi >0.9) 
Figure 3
Oligogenicity is a common factor in CHH, and it is not found 
in CDGP. Histogram showing the frequency of KS (red), nCHH 
(yellow), CHH (orange), CoLaus (blue) and CDGP (green) 
individuals having no rare variants in CHH genes, one gene 
mutated or at least two genes mutated (oligogenicity). 
Differences between KS, nCHH and CHH vs CoLaus controls 
were analyzed via a two-sided Fisher’s exact test. P < 0.05 was 
considered significant. *P < 0.05; **P < 0.01; ***P < 0.001; 
****P < 0.0001. Not significant differences among KS, nCHH 
and CHH vs CoLaus are not displayed.
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
178:4 384Clinical Study D Cassatella and others Diverse genetic patterns in CHH 
and CDGP
www.eje-online.org
(28), a higher frequency than in ExAC controls (P = 0.002). 
Conversely, the majority of PTVs in ExAC (60%) were present 
in PTV-tolerant genes (pLi <0.1) (Fig.3 and Supplementary 
Fig.  4). Furthermore, a large majority of PTVs found in 
CHH probands (16/20, 80%) are heterozygous and occur in 
CHH genes where mutations are inherited in an autosomal 
dominant mode. Moreover, all of the PTVs identified 
in CHH probands likely result in haploinsufficiency, as 
they do not lie within the last exon (or in last 50 bp of 
penultimate exon) and are therefore likely to be subjected 
to nonsense-mediated decay (NMD) (35).
Discussion
CDGP and CHH are part of a continuum of GnRH 
deficiency, ranging from transiently delayed to a 
complete absence of puberty. However, it is challenging 
to make a clinical distinction between CHH and CDGP 
in adolescents presenting with delayed puberty. In this 
study, we investigated the genetic overlap between these 
two conditions focusing on rare variants in known 
CHH genes and IGSF10, a gene recently identified in 
CDGP. CHH and CDGP differ in terms of the number of 
patients harboring mutations in individual CHH genes 
(51% vs 7%), as well as the overall mutational load in 
CHH genes (oligogenicity). In both instances, the CDGP 
probands more closely resembled the control cohort. 
We also observed similar frequencies of putative IGSF10 
mutations in CDGP and CHH probands, although 
higher than previously reported (19). It is important to 
note, however, that the previous study by Howard and 
coworkers utilized a different filtering strategy to identify 
low-frequency variants, specifically focusing on variants 
with MAF of <2.5% – a level consistent with the frequency 
of CDGP. Notably, the present study focused on variants 
with MAF <1.0% given the rarity of the CHH phenotype. 
Thus, it is not surprising that different results would be 
achieved. This would suggest that variants with MAF 
1.0–2.5% may contribute more strongly to the CDGP 
phenotype. Indeed, the most frequent IGSF10 variant in 
the CDGP cohort (p.Glu161Lys) has a MAF of 2.0% in 
the Finnish population. In the current study, the variants 
identified have not been functionally validated nor has 
segregation with trait within pedigree been analyzed, 
both of which were used to identify definitive pathogenic 
variants in the previous study by Howard and coworkers. 
Furthermore, the lack of an association of IGSF10 
mutations with CDGP or CHH in the current study may 
reflect a limitation of rare variant burden testing. It is 
possible that in a very large gene such as IGSF10, there 
may be a large number of non-causal variants or both 
Figure 4
FGFR1 and CHD7 are frequently inherited 
in digenic fashion among CHH probands. 
(A) Matrix showing shading-coded 
frequencies CHH genes digenic 
combinations. (B) Available pedigrees of 
CHH probands displaying oligogenic 
inheritance. Circles denote females; 
squares denote males; arrows depict 
probands; WT denotes wild-type.
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protective and deleterious variants, and the proportion 
of these may vary between different populations. In 
summary, the current data show that the genetic profile 
of the Finnish CDGP patients, while enriched for rare 
putative pathogenic variants in IGSF10 as compared to 
ethnically matched controls, closely resemble the profile 
of both ExAC Finnish and non-Finnish control cohorts 
with respect to known CHH genes.
Recent GWAS studies have identified hundreds of loci 
associated with puberty onset in the general population 
(20, 21), with several signals lying close to or within CHH 
genes suggestive of a genetic overlap between CHH and 
CDGP. However, GWAS signals may result from intergenic, 
intronic, promoter or other regulatory changes that are 
not detected by exome sequencing. Therefore, our results 
in CHH and CDGP patients could have missed pathogenic 
mutations in regulatory regions. Notably, a genome-wide 
significant signal in the coding sequence was reported in 
TACR3 (p.Trp275*), a mutation identified in nCHH in this 
report as well as in previous studies (8, 36, 37). Although 
prior GWAS studies have not identified an association 
for its ligand TAC3, we identify mutations in TAC3 in 
both CHH and CDGP cohorts. Further, TAC3 mutations 
were previously reported in CHH as well as CDGP 
(3). Combined, these data implicate the neurokinin B 
pathway in both CHH and CDGP. We propose that larger 
studies examining pathways rather than individual genes 
identified by GWAS are required to further elucidate the 
genetic overlap between CHH and CDGP.
Using whole exome sequencing to examine a larger 
number of CHH genes in our study, we identified mutations 
in 51% of CHH cases. This is increased in relation to prior 
reports of 31% (10) and 35% (8) respectively. Our data are 
mostly consistent with a recent publication by Francou 
et al. (38) that evaluated a large cohort of nCHH patients 
of European descent for pathogenic variants in KISS1R, 
GNRHR, TACR3, KISS1, TAC3 and GNRH1.
We report a genetic overlap between KS and nCHH. 
Using a gene-collapsed rare variant association study 
(RVAS) on the entire CHH cohort, we found significant 
associations for FGFR1, CHD7 and SOX10. Separating 
CHH into KS and nCHH, the burden test remained 
significant for FGFR1 in both subgroups while CHD7 and 
SOX10 were significant only for KS. Notably, significant 
association appears for FGF8 in KS while GNRHR, TACR3 
and KISS1 showed association only in nCHH. A significant 
enrichment of rare variants in the RNF216 gene was 
recently shown in patients with CHH and cerebellar ataxia 
(39). In contrast, no enrichment in KISS1 rare variants 
was detected in 1025 CHH patients, without respect to 
the phenotypic subgroups (12). These data point toward 
the importance of phenotypic clustering to identify novel 
associated genes (8, 40). Finally, our results show that such 
burden tests might miss associations in important genes 
like KISS1R, because of the low frequency of rare variants 
in both patient and control population.
Oligogenicity occurs in our study in 15% of CHH 
cases as compared to 2.5% and 7% in previous reports 
(8, 10) using nearly identical strategies for variant 
classification. This increase is due in part to the 
increased number of CHH genes screened using exome 
sequencing. Although this study does not provide 
molecular evidences of oligogenic interactions, previous 
studies demonstrated that oligogenicity is a critical 
factor in CHH pathogenesis (8, 11, 41). Recent guidelines 
from the American College of Medical Genetics aid in 
the identification of pathogenic variants in a clinical 
setting (42). While these guidelines are suited only 
for monogenic disorders, they do provide a structured 
framework from which to evaluate variants. Using these 
guidelines, all ACMG pathogenic or likely pathogenic 
variants were also classified as pathogenic in the current 
study (Supplementary Table 2). However, a large number 
of pathogenic variants detected in the current study 
were classified as unknown significance using ACMG 
guidelines. This is primarily due to the weight assigned 
to (i) familial segregation that is not applicable in the 
setting of oligogenicity and (ii) detection of de novo 
mutations that was not possible in this study as parental 
DNA was not available for most probands.
The combination of mutations in both FGFR1 and 
CHD7 occurred most frequently (n = 4 probands). These 
two genes might play coordinated roles during GnRH 
neuron development and migration as CHD7 regulates 
the transcription of Fgf8, a major ligand for FGFR1 in 
GnRH neuron ontogeny (11). Moreover, both FGFR1 and 
CHD7 are expressed in relevant tissues for CHH, such as 
the olfactory bulb and hypothalamus (43). A previous 
report also suggested functional interactions between 
these genes, as CHH patients with mutations in FGFR1 
and CHD7 exhibit overlaps in associated phenotypes 
(cleft lip/palate, coloboma or ear anomalies) (44).
One notable exception to oligogenicity was ANOS1 – 
which was inherited in an exclusively monoallelic fashion 
due to its X-linked recessive mode of inheritance and 
high penetrance. Mutations in other genes such as TAC3, 
KISS1, PROK2 and PROKR2 were primarily biallelic and 
oligogenic interactions were not observed – likely due 
to their recessive mode of inheritance. Interestingly, the 
frequency of monogenic inheritance in KS was significantly 
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higher than in nCHH. To date, it is unclear whether this 
difference is due to distinct genetic architecture or that 
‘missing’ partners in an oligogenic inheritance for KS 
have yet to be discovered.
We discovered putatively pathogenic mutations in 
CHH genes in up to 17% of controls, which at first glance 
seems counterintuitive. Importantly, oligogenicity was 
only rarely found in controls (2%), further supporting the 
oligogenic model of CHH pathogenesis. Additionally, many 
of the putative heterozygous mutations in controls were 
found in genes with an autosomal recessive inheritance, 
which would explain the lack of obvious reproductive 
phenotypes among controls. Further, CHH and controls 
differ markedly for PTVs (29% vs 5%, respectively), and 
the PTVs in controls were less likely to be pathogenic.
This study expands our understanding of the genetic 
architecture of both CHH and CDGP and highlights 
the very large proportion of cases of CDGP that are not 
explained by mutations in known genes. Further, the 
genetic profiles of CHH and CDGP appear to be distinct 
with respect to the 25 CHH genes studied here, with the 
understanding that ethnic differences between groups 
(European vs Finnish) could contribute to this finding. 
This observation may facilitate differential diagnosis of 
CHH and CDGP in early adolescence when a clear and 
early diagnosis is critical to initiate timely induction of 
puberty in patients with CHH. A genetic test resulting in 
(1) more than one CHH gene mutated (oligogenicity), 
(2) hemizygous ANOS1 mutations in male patients or (3) 
biallelic mutations in genes associated with autosomal 
recessive inheritance would favor a diagnosis of CHH. 
Additional comprehensive studies in larger cohorts may 
enable genetic testing to inform a more precise differential 
diagnosis in the clinical setting.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EJE-17-0568.
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